KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 88 Publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 NUTVZo14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTNwMkezOVIh|ryP MoDNV2FPT0WU
HuO-3N1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjE[WpKSzVyPUSuNVcyPDJizszN MmfCV2FPT0WU
LAMA-84 NEj4Z4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRwNUi0OlUh|ryP NWnrfoVQW0GQR1XS
CAL-72 NIjDToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHlTWM2OD13LkS4NFg1KM7:TR?= Mnj1V2FPT0WU
LoVo M{SzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnBTJhKSzVyPU[uPVMzOzlizszN NImybpdUSU6JRWK=
HH NVfocpg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3frZWlEPTB;OD6yO|Y4OSEQvF2= M3n6WnNCVkeHUh?=
SK-MEL-3 M1X2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PZ[GlEPTB;OD6yPFU4PSEQvF2= MoO5V2FPT0WU
KM12 M{O5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTlwMkGxOFIh|ryP MYHTRW5ITVJ?
NCI-H1437 NFH4VZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISxWJRKSzVyPUmuPFA6PyEQvF2= M1G5SXNCVkeHUh?=
NCI-H1838 M{j5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\QTWM2OD1zMT6xPFY2KM7:TR?= NXTT[Fd1W0GQR1XS
J-RT3-T3-5 NXzNO2g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV31SlZ7UUN3ME2xNU4zPDF5IN88US=> M4XFN3NCVkeHUh?=
GOTO MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i2dGlEPTB;MUGuOlk6PiEQvF2= M3fPWHNCVkeHUh?=
LB2241-RCC NFX1fVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nUVmlEPTB;MUGuO|E5PiEQvF2= NE[1VZdUSU6JRWK=
ES7 Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHUOIFVUUN3ME2xNU44QDhizszN MlniV2FPT0WU
KP-N-YS MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XCPGlEPTB;MUKuOlM2PCEQvF2= M4rCO3NCVkeHUh?=
CAL-12T NYTOUHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO0WIdtUUN3ME2xN{43OTdizszN NGDUfpBUSU6JRWK=
COLO-684 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF2LkG1Olkh|ryP NYLpNFlWW0GQR1XS
DOK MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTNTWM2OD1zNT6zN|I6KM7:TR?= NGfTeHRUSU6JRWK=
Hs-578-T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fPb2lEPTB;MUWuOFE5OiEQvF2= MVrTRW5ITVJ?
D-423MG NI\Ub4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXHTWM2OD1zNT61NlM3KM7:TR?= NUfnTGp[W0GQR1XS
DBTRG-05MG M164VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljHTWM2OD1zNT62NVEyKM7:TR?= M3TpeHNCVkeHUh?=
VM-CUB-1 NYq0XXAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW2cJUyUUN3ME2xOU46QDR7IN88US=> M2PxW3NCVkeHUh?=
KG-1 NWLXbJh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi5TWM2OD1zNj6wPVk3KM7:TR?= M2\Q[3NCVkeHUh?=
8305C MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDoR5VmUUN3ME2xOk4yQDh7IN88US=> NVG1eIFQW0GQR1XS
HuH-7 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF4LkK2O|Qh|ryP MkS5V2FPT0WU
LXF-289 NHH4N2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYToOIF7UUN3ME2xOk4zPzR5IN88US=> NI\nOmdUSU6JRWK=
NCI-H1793 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW3cnhKSzVyPUG2MlQ4OTJizszN NEXERYRUSU6JRWK=
ChaGo-K-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17aNmlEPTB;MU[uOlU3QCEQvF2= Moe0V2FPT0WU
GCIY M3XVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TyeWlEPTB;MU[uO|kxPSEQvF2= NY\zeo8{W0GQR1XS
SK-MEL-28 M3O0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF5LkC0O|Uh|ryP NIrFSWFUSU6JRWK=
NCI-SNU-1 NHHUeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfYbIZNUUN3ME2xO{4yOjZ7IN88US=> M2DKeHNCVkeHUh?=
CTB-1 NHvMN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVntZZE3UUN3ME2xO{4zOjV7IN88US=> NEfNRWRUSU6JRWK=
NCI-H82 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHNUJd7UUN3ME2xO{41PTd|IN88US=> MYPTRW5ITVJ?
HCC2998 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF5Lk[3N|Mh|ryP NGTCe2ZUSU6JRWK=
NCI-H2030 MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF6LkG5PVch|ryP NYjLPFJuW0GQR1XS
HuP-T3 MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\kR4RKSzVyPUG4MlU5QDhizszN NFz6VYdUSU6JRWK=
697 NIHIeo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDwTWM2OD1zOT6wNlAyKM7:TR?= NFjsN5BUSU6JRWK=
MLMA NGr3c3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rUb2lEPTB;MUmuNFU2PyEQvF2= MW\TRW5ITVJ?
HCC70 M{GyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF7LkS4PUDPxE1? MonIV2FPT0WU
A704 NFzEVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PXRmlEPTB;MUmuPFMxPSEQvF2= MoP2V2FPT0WU
D-283MED M{fsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPOdnpKSzVyPUKwMlU{OzlizszN M3HGW3NCVkeHUh?=
U031 NHmwXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrCTWM2OD1{MT6xOFg6KM7:TR?= NULnU|cxW0GQR1XS
HSC-3 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\ySGlEPTB;MkGuNVg{PSEQvF2= NG\yN|JUSU6JRWK=
JVM-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJ{LkWwOkDPxE1? M1PSbnNCVkeHUh?=
Mewo M2DRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ{LkWwO|Mh|ryP NG[yWHpUSU6JRWK=
YH-13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH3OpN2UUN3ME2yNk42OTJ|IN88US=> M2nHfXNCVkeHUh?=
LB1047-RCC NUPRT457T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfENWlKSzVyPUKyMlU5PzlizszN MY\TRW5ITVJ?
HCC2157 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj2TWM2OD1{Mj64NFU1KM7:TR?= MVHTRW5ITVJ?
SNU-449 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnWTWM2OD1{Mj64O|Q5KM7:TR?= M{j2XnNCVkeHUh?=
Ramos-2G6-4C10 NI\nRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjNXmxKSzVyPUKyMlk3KM7:TR?= M{\CPXNCVkeHUh?=
CHL-1 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fjVWlEPTB;MkOuO|I6OiEQvF2= NUTZbnZbW0GQR1XS
SK-MEL-30 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ2LkS2OlIh|ryP M4HX[HNCVkeHUh?=
PANC-08-13 NFPGfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJ3LkC5N|gh|ryP NGCyPVhUSU6JRWK=
QIMR-WIL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XwWWlEPTB;MkWuNVg2QCEQvF2= NFrnVYdUSU6JRWK=
BFTC-905 M2G4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXRNYFKSzVyPUK1MlU6PDRizszN M4PvPHNCVkeHUh?=
GI-1 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MliyTWM2OD1{NT63NFU2KM7:TR?= M2nZd3NCVkeHUh?=
MDA-MB-415 NVjZSmQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK4Oo1TUUN3ME2yOk42ODN|IN88US=> Ml7jV2FPT0WU
GT3TKB M4XJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInFdmhKSzVyPUK2MlU{PDJizszN Mo\UV2FPT0WU
DEL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjmTWM2OD1{Nj64N|U3KM7:TR?= M3HxS3NCVkeHUh?=
KOSC-2 M{L1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ4LkmwO|Uh|ryP NG\pWpFUSU6JRWK=
RVH-421 NHjyWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorRTWM2OD1{Nz6yPVIyKM7:TR?= MX7TRW5ITVJ?
EW-13 NIDhbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofnTWM2OD1{Nz60N|A5KM7:TR?= MYnTRW5ITVJ?
639-V M37ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\TUWxNUUN3ME2yO{42OTF7IN88US=> MXzTRW5ITVJ?
A2780 NWrq[Y9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ5Lk[0NUDPxE1? M4HxT3NCVkeHUh?=
SW982 M1[4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK4W|JzUUN3ME2yO{46ODV{IN88US=> NYrYWFViW0GQR1XS
SW1710 M3rNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\qUpdVUUN3ME2yPE4xQThzIN88US=> NVL2NZdLW0GQR1XS
HCC1569 M1LpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJ6LkS4PVch|ryP M4r1e3NCVkeHUh?=
MV-4-11 NVHhTlF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33Q[WlEPTB;MkiuOVc{PSEQvF2= M{HwOnNCVkeHUh?=
BHT-101 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[xW|JKSzVyPUK4MlY2PzJizszN NVTYflJHW0GQR1XS
Ca9-22 M4TWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf3TWM2OD1{OD63NVQh|ryP MljUV2FPT0WU
HAL-01 NHe1epJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvmeYRKSzVyPUK4Mlc3OTVizszN M3rIfnNCVkeHUh?=
D-263MG MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjqTWM2OD1{OT6zOFQh|ryP MmXGV2FPT0WU
NEC8 NUTNNlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j2emlEPTB;MkmuOVU1QCEQvF2= M1rpcXNCVkeHUh?=
EKVX MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNzLkW4OFch|ryP NVrkSlliW0GQR1XS
EM-2 NHTWNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLLPGF5UUN3ME2zNU43OzB2IN88US=> M4n0R3NCVkeHUh?=
MFM-223 NVruVZhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PaRWlEPTB;M{GuPFA6QCEQvF2= MnG2V2FPT0WU
SK-PN-DW MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO0RXhyUUN3ME2zNk4yPDB4IN88US=> MkPyV2FPT0WU
HuO9 NIm2NJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN{LkWyPFIh|ryP NVHab4s5W0GQR1XS
MHH-PREB-1 NX\EOVRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTN{Lk[yN|Qh|ryP NIHEc3FUSU6JRWK=
OVCAR-4 NGLROoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH64R4RKSzVyPUOyMlg{PjNizszN NV20PIJSW0GQR1XS
NCI-H1648 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTN{Lki2OVEh|ryP Mlu2V2FPT0WU
MKN1 NWj6UmNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvEO2d1UUN3ME2zOE4yOTBzIN88US=> MnHUV2FPT0WU
KYSE-450 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP6TWM2OD1|ND62OFQ1KM7:TR?= MVzTRW5ITVJ?
ES8 NXP5WXJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN2Lki5O|Uh|ryP M4LSNnNCVkeHUh?=
MS-1 NGTxZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTNTWM2OD1|ND65OVU1KM7:TR?= M4XISnNCVkeHUh?=
HOP-92 MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K2UGlEPTB;M{WuPVI4PyEQvF2= Mnj4V2FPT0WU
SKG-IIIa NGntV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn30TWM2OD1|Nj6yOVYyKM7:TR?= NV\6NIxYW0GQR1XS
TE-11 M17WTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTN4LkWyOFMh|ryP M334VnNCVkeHUh?=
SK-NEP-1 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf0R5VKSzVyPUO3MlY4PDRizszN MnXxV2FPT0WU
DB NGSxT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPVbodKSzVyPUO3MlkyQDVizszN MlHGV2FPT0WU
IA-LM M2GxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfYZoJ7UUN3ME2zPE4xOjN7IN88US=> MV;TRW5ITVJ?
COLO-829 M2\uR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\STWM2OD1|OD60NVU6KM7:TR?= MVjTRW5ITVJ?
TGBC11TKB NXHjNIRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN7LkG0NFgh|ryP M{LMOHNCVkeHUh?=
CAL-51 M33QO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnTN3Y5UUN3ME20NE4xPjF{IN88US=> Mn;pV2FPT0WU
NCI-H2228 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTRyLkO2OlIh|ryP NULyVphUW0GQR1XS
C32 M4nDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XObGlEPTB;NECuOFAzPCEQvF2= M3L6NXNCVkeHUh?=
KU-19-19 NXH2NJo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfiNJRKSzVyPUSwMlc3QDNizszN M1vKTXNCVkeHUh?=
KNS-62 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRyLkizPFEh|ryP NH3P[HhUSU6JRWK=
FADU M4TGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrue3VvUUN3ME20NU4zPTB{IN88US=> NGTRco5USU6JRWK=
CAL-33 NXfGb25NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTR{Lk[3OFkh|ryP M3zqUnNCVkeHUh?=
CHP-134 NID3W5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfycZVKSzVyPUSyMlg1QTZizszN M33lXnNCVkeHUh?=
HDLM-2 NVv4V5k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWToSHhzUUN3ME20Nk46ODh2IN88US=> MoDvV2FPT0WU
NBsusSR M{nLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;pdYVKSzVyPUSzMlA4OjVizszN NV60[m5XW0GQR1XS
SW954 NF64NYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG5eY9VUUN3ME20N{4yODV|IN88US=> M4O0TnNCVkeHUh?=
HCC1806 NEnhSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR|LkSxNUDPxE1? M{XoNnNCVkeHUh?=
VMRC-RCZ M3v3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;Oe5NKSzVyPUSzMlQ2QDZizszN NGLnd3RUSU6JRWK=
A549 NIeyNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTR|LkmzNUDPxE1? MnjQV2FPT0WU
NKM-1 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPlTWM2OD12Mz65OVU5KM7:TR?= MWHTRW5ITVJ?
DMS-273 MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTR2Lke1Olch|ryP MWTTRW5ITVJ?
TYK-nu NH3XfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfKfmk3UUN3ME20OU4yOjN2IN88US=> NWW0dItRW0GQR1XS
KALS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV20d|NKUUN3ME20OU4yPDZizszN MlfzV2FPT0WU
A101D M3LMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HVPWlEPTB;NEWuOFQ2PiEQvF2= NXj0eIVvW0GQR1XS
G-361 NUW1XGwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR4LkKxN|gh|ryP NH:3c4NUSU6JRWK=
KARPAS-299 NEjY[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3exbGlEPTB;NE[uN|UyPiEQvF2= NVTuNmhHW0GQR1XS
RS4-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\VTWM2OD12Nj61OFIh|ryP M{nJU3NCVkeHUh?=
HT-1376 NEnWbY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7yTWM2OD12Nj63OFI3KM7:TR?= MV3TRW5ITVJ?
SK-N-AS Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rnUmlEPTB;NE[uO|gzOiEQvF2= NUTEflNlW0GQR1XS
MG-63 NU[zN3Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHLTWM2OD12Nj65NFM3KM7:TR?= NF\qPIhUSU6JRWK=
EPLC-272H NEiwO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjYcoVKSzVyPUS2Mlk2ODNizszN MmPSV2FPT0WU
BALL-1 NE[zNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXnTWM2OD12Nz64N|Ih|ryP NICxR2VUSU6JRWK=
LCLC-97TM1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1SzTWlEPTB;NEiuNlAzKM7:TR?= NVPOWI5WW0GQR1XS
HO-1-N-1 NVHi[VJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH31b5FKSzVyPUS4Mlk3PzZizszN MoDyV2FPT0WU
MFE-280 NUO1fY9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDo[ohLUUN3ME20PU41PjF5IN88US=> NYfUSZc5W0GQR1XS
NCI-H526 NWDMcFB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO1ZWIyUUN3ME20PU45OTZ|IN88US=> M1;vZ3NCVkeHUh?=
D-566MG NEPiOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG3TWM2OD12OT65NFk3KM7:TR?= NVXpVG51W0GQR1XS
BB30-HNC M1jWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D4OWlEPTB;NEmuPVQ6QCEQvF2= NXLRdG1zW0GQR1XS
SK-N-DZ NIj4dI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTVTWM2OD13MD6wOFgyKM7:TR?= M4TrOXNCVkeHUh?=
HepG2  M1XYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTtNVDDqM7:TR?= NX;jd2dTOjRiaB?= MnPjZoxw[2u|IGPDMWlKUTNvaX7keYNm\CCVIIDoZZNmKGG{cnXzeC=> M4\qXFI2PTJ5MUKz
HepG2  NX\p[oN5TnWwY4Tpc44hSXO|YYm= NHHKblkyOMLizszN NVj0SJdOOjRiaB?= NUL4UXdxe3WycILld5NmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wczDv[kBCXE1ib36gV4VzOTl6MTygR4hsOSCxbjDT[ZI{PDVuIFPob|Ihd25iVHjyOlgtKGGwZDDD[IszKG:wIGT5dlE2KGmwZIXj[YQh[nliU1OtTWlKOw>? NGrDbHozPTV{N{GyNy=>
KATO III  NGPE[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\SNk42NzVxNz61JO69VQ>? NHLRb2tFVVOR MmKx[Y5p[W6lZYOgeIhmKHSxeHnjbZR6KG:oIH;sZZBiemmk NWm3Rm5{OjR6NEG3NVg>
hTCEpi MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ywV|ExKM7:TR?= MV7EUXNQ NFW0eGxxemW4ZX70d{B1cGViY4n0c5BifGirYzDl[oZm[3Rib3[gTHNXNTF? M13jWVI1OzdyOEO1
MCF10A MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT1Zmh6OTBizszN NGfGb4czPCCq NH7DfYJFVVOR Ml33dI91\W62aXH0[ZMhfGinIHP5eI91d3irY3n0fUBw\iCJQR?= NHP2U4QzPDF3MEW5OS=>
HL-60  MWDGeY5kfGmxbjDBd5NigQ>? MWixNEDPxE1? Ml[zNE42KGh? NEjxeY5FVVOR M1v4dJJm\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNpczMEoB?= NX3xOllXOjN7M{S0NVE>
MCF-7 M2fjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:xMVExOM7:TR?= NX;aVY9oOjRiaB?= MlLWSmJU NWSyeZh7cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= NEfIR3ozOzF6NUO0Oy=>
HeLa  M1XQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTONU0yODEQvF2= M33kVVI1KGh? M{\TZWZDWw>? NYSxXGV{cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= Mlv1NlMyQDV|NEe=
SH-SY5Y M3L1S2Z2dmO2aX;uJGF{e2G7 M{jsWVExyqEQvF5CpC=> MWmyOEBp NVfYV3dVcW6qaXLpeJMh[2yrb4H1bY5wdC2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCyNUO= MorWNlI3Ojd{OUS=
IMR-32 NEPzZ|FHfW6ldHnvckBCe3OjeR?= NULaeZc2OTEEoN88UeKh MkPnNlQhcA>? MnzIbY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? MUeyNlYzPzJ7NB?=
A549 MXnGeY5kfGmxbjDBd5NigQ>? MoKwNVDDqM7:TdMg NVP6SnpXOSCq MV\zeZBxemW|c3XzJG5idm9vQ3:tbY5lfWOnZDDwOVMh[WOldX31cIF1cW:w MW[yNlU2QTN{MR?=
T47D  NYSzNVZKTnWwY4Tpc44hSXO|YYm= NV;vUINzOjEEoH3N Mn64NlQhcA>? M1znemROW09? MX\wdoV3\W62czDJVk1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFpOvmLPuQ>? NHnBWG0zOTF2NEiwOS=>
A29 MEF M{fnbmZ2dmO2aX;uJGF{e2G7 NXTpVoJYOTEEoN88UeKh NUW3R|BsOWh? MnfOZoxw[2u|wrD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGtdDDheEBU\XJ2N{RCpC=> NIXudlUzODB3M{e4NS=>
MDA-MB-453  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O3XlUuPDBizszN NITHSHc4OiCq MV;JR|UxKG:oIEGwJO69VQ>? NW[z[XlbOjByNUO3PFE>
PC-3 NWnEOWtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV21MVQxKM7:TR?= MWK3NkBp MVPJR|UxKG:oIEGwJO69VQ>? NXzmcWpbOjByNUO3PFE>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]
+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]
+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO and 47.5% PEG300
For best results, use promptly after mixing. 		10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2
CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

  • AZD6738 New

    AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.

  • Dorsomorphin (Compound C) New

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • VE-821

    VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.

  • KU-60019

    KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.

    Features:Improved analog of KU-55933, and is more effective at blocking ATM-mediated DDR events.

  • Berzosertib (VE-822|VX970|M6620)

    VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.

    Features:VE-822 is a highly selective and potent derivative of the ATR inhibitor VE-821.

  • Chloroquine diphosphate

    Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator.

  • AZ20

    AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.

    Features:AZ20 is the first reported inhibitor of ATR protein kinase demonstrating tumor growth inhibition in vivo.

  • CP-466722

    CP-466722 is a potent and reversible ATM inhibitor, does not affect ATR and inhibits PI3K or PIKK family members in cells.

  • ETP-46464

    ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

    Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID